RGEN
Repligen Corporation158.09
-2.49-1.55%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
8.90BP/E (TTM)
7904.50Basic EPS (TTM)
0.02Dividend Yield
0%Recent Filings
10-Q
8-K
Q3 revenue beats, guidance up
Repligen Corporation reported third-quarter 2025 revenue of $189 million, up 22% reported and 18% organic from $155 million a year earlier, with double-digit growth across all franchises and geographies. Orders surged over 20% year-over-year, fueling broad momentum in consumables and capital equipment. The company raised full-year revenue guidance to $729-$737 million, signaling 14%-15.5% non-COVID organic growth. Strong execution persists, yet integration costs linger.
8-K
Repligen appoints new CAO
Repligen Corporation appointed Violetta Hughes as Chief Accounting Officer effective September 1, 2025, to strengthen financial reporting and Sarbanes-Oxley compliance. Hughes, with over 25 years in life sciences finance from roles at Azenta and Akebia, replaces Jason Garland in that capacity while he shifts to strategy and growth. Her package includes $395,000 base salary, $150,000 signing bonus, 50% target bonus, and $750,000 equity vesting over five years. This bolsters governance amid expansion.
10-Q
Q2 FY2025 results
Repligen posted solid Q2 results, with revenue climbing 14.8% year-over-year to $182.4M on stronger chromatography and analytics sales, while six-month totals rose 12.7% to $351.5M. Operating income jumped to $13.9M from $5.5M last year, thanks to a $7.9M gain from lower contingent consideration tied to Tantti, though gross margins dipped to 50.0% from 51.3% on product mix shifts. Diluted EPS held steady at $0.26, aligning with 56.5M shares and no anti-dilution from the $600M 2028 notes. Cash at $708.9M funded the March 2025 $69.9M 908 Devices PAT Portfolio buy, adding $50.1M goodwill and $13.6M intangibles over 8-14 years; free cash flow came in at $30.6M after $13.0M capex. Acquisitions bolster new modalities, yet integration costs linger. Restructuring wrapped up, but supply chain volatility poses risks.
8-K
Repligen boosts Q2 revenue, guidance
Repligen Corporation reported Q2 2025 revenue of $182 million, up 15% year-over-year and 17% on an organic non-COVID basis, fueled by over 20% consumables growth and high-teens capital equipment gains across all franchises and geographies. Orders surged more than 20% year-over-year, marking eight straight quarters outpacing non-COVID revenue. The company raised full-year revenue guidance to $715-$735 million, signaling 12.5%-15.5% organic non-COVID growth despite new modality headwinds. Momentum builds, yet tariffs pose a modest drag.
IPO
Website
Employees
Sector
Industry
AVTR
Avantor, Inc.
11.20-0.08
CLGN
CollPlant Biotechnologies Ltd.
1.53-0.14
DHR
Danaher Corporation
224.70-3.83
ORGO
Organogenesis Holdings Inc.
5.17+0.34
QGEN
Qiagen N.V.
45.01-0.43
RGNT
Regentis Biomaterials Ltd.
6.05-0.84
RSCF
Reflect Scientific, Inc.
0.05+0.00
RVTY
Revvity, Inc.
96.27-2.81
SOAGY
Sartorius AG
56.43-0.16
TECH
Bio-Techne Corp
57.44-1.25